Calcium phosphate: an alternative calcium compound for dietary prevention of colon cancer? A study on intestinal and faecal parameters in healthy volunteers.
In an effort to reduce the risk of colorectal cancer development, oral calcium carbonate supplementation has been used in previous studies for the precipitation of cytotoxic bile acids and fatty acids. In human intervention trials its effect on mucosal hyperproliferation in the colorectum has not always been satisfactory. Because the complexation of calcium and bile acids requires the formation of calcium phosphate, we performed an intervention study in 14 healthy volunteers, giving them 1,500 mg calcium as Ca3(PO4)2 for 1 week. The effects of tricalcium phosphate on luminal and faecal parameters of cytolytic activity were evaluated before, during, and after calcium phosphate supplementation. The cytolytic activity of faecal water and intestinal alkaline phosphatase activity in faecal water were not affected by supplemental calcium phosphate. In duodenal bile, the proportion of cholic acid tended to increase, whereas that of chenodeoxycholic acid tended to decrease during calcium phosphate supplementation. Neither concentrations of total and individual faecal bile acids, nor that of faecal fat were affected during calcium phosphate supplementation. It is suggested that, although phosphate is involved in bile acid precipitation, phosphate competes for calcium in the binding of fatty acids. This might possibly explain the unchanged cytolytic potency of faecal water, and therefore does not make tricalcium phosphate a suitable calcium compound for dietary intervention.
Cats
A
A
Department of Internal Medicine, University Hospital, Groningen, The Netherlands.
Mulder
N H
NH
de Vries
E G
EG
Oremus
E T
ET
Kreumer
W M
WM
Kleibeuker
J H
JH
D000328:Adult; D000469:Alkaline Phosphatase / Q000032:analysis; D001647:Bile Acids and Salts / Q000032:analysis; D002130:Calcium Phosphates / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D002136:Calcium, Dietary / Q000494:pharmacology* / Q000627:therapeutic use; D003106:Colon / Q000166:cytology / Q000187:drug effects*; D003110:Colonic Neoplasms / Q000517:prevention & control*; D003603:Cytotoxins; D004386:Duodenum; D005240:Feasibility Studies; D005243:Feces / Q000737:chemistry / Q000201:enzymology; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007419:Intestinal Secretions / Q000737:chemistry; D008055:Lipids / Q000032:analysis; D008297:Male
D001647:Bile Acids and Salts; D002130:Calcium Phosphates; D002136:Calcium, Dietary; D003603:Cytotoxins; D008055:Lipids; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; C485838:calcium phosphate, monobasic, anhydrous; C020243:calcium phosphate; D000469:Alkaline Phosphatase; C485829:calcium phosphate, dibasic, anhydrous